Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 285

1.

IUPHAR International geriatric clinical pharmacology curriculum for medical students.

Kashyap M, Thuermann P, Le Couteur DG, Abernethy DR, Hilmer SN.

Pharmacol Res. 2019 Mar;141:611-615. doi: 10.1016/j.phrs.2019.01.032. Epub 2019 Jan 17. No abstract available.

PMID:
30660820
2.

Pharmacotherapy in Older Adults with Cardiovascular Disease: Report from an American College of Cardiology, American Geriatrics Society, and National Institute on Aging Workshop.

Schwartz JB, Schmader KE, Hanlon JT, Abernethy DR, Gray S, Dunbar-Jacob J, Holmes HM, Murray MD, Roberts R, Joyner M, Peterson J, Lindeman D, Tai-Seale M, Downey L, Rich MW.

J Am Geriatr Soc. 2019 Feb;67(2):371-380. doi: 10.1111/jgs.15634. Epub 2018 Dec 7. Review.

3.

β2-adrenoceptor agonists and antagonists and risk of Parkinson's disease.

Gronich N, Abernethy DR, Auriel E, Lavi I, Rennert G, Saliba W.

Mov Disord. 2018 Sep;33(9):1465-1471. doi: 10.1002/mds.108.

PMID:
30311974
4.

Drug Burden Index and Its Association With Hip Fracture Among Older Adults: A National Population-Based Study.

Jamieson HA, Nishtala PS, Scrase R, Deely JM, Abey-Nesbit R, Hilmer SN, Abernethy DR, Berry SD, Mor V, Lacey CJ, Schluter PJ.

J Gerontol A Biol Sci Med Sci. 2019 Jun 18;74(7):1127-1133. doi: 10.1093/gerona/gly176.

PMID:
30084928
5.

Drug Burden and its Association with Falls Among Older Adults in New Zealand: A National Population Cross-Sectional Study.

Jamieson HA, Nishtala PS, Scrase R, Deely JM, Abey-Nesbit R, Connolly MJ, Hilmer SN, Abernethy DR, Schluter PJ.

Drugs Aging. 2018 Jan;35(1):73-81. doi: 10.1007/s40266-017-0511-5.

PMID:
29222667
6.

Improving Therapeutics to Better Care for Older Adults and the Young: Report From the American College of Clinical Pharmacology Workshop.

Lau SWJ, Schlender JF, Abernethy DR, Burckart GJ, Golden A, Slattum PW, Stegemann S, Eissing T.

J Clin Pharmacol. 2018 Mar;58(3):277-280. doi: 10.1002/jcph.1024. Epub 2017 Oct 11. No abstract available.

PMID:
29023776
7.

Use of Biomedical Ontologies for Integration of Biological Knowledge for Learning and Prediction of Adverse Drug Reactions.

Zaman S, Sarntivijai S, Abernethy DR.

Gene Regul Syst Bio. 2017 Mar 15;11:1177625017696075. doi: 10.1177/1177625017696075. eCollection 2017. Review.

8.

In Vitro-In Vivo Extrapolation of Metabolism- and Transporter-Mediated Drug-Drug Interactions-Overview of Basic Prediction Methods.

Yoshida K, Zhao P, Zhang L, Abernethy DR, Rekić D, Reynolds KS, Galetin A, Huang SM.

J Pharm Sci. 2017 Sep;106(9):2209-2213. doi: 10.1016/j.xphs.2017.04.045. Epub 2017 Apr 26. Review.

PMID:
28456729
9.

Tyrosine kinase-targeting drugs-associated heart failure.

Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G.

Br J Cancer. 2017 May 9;116(10):1366-1373. doi: 10.1038/bjc.2017.88. Epub 2017 Apr 11.

10.

GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near-Term Efforts in the Field.

Musante CJ, Abernethy DR, Allerheiligen SR, Lauffenburger DA, Zager MG.

CPT Pharmacometrics Syst Pharmacol. 2016 Sep;5(9):449-51. doi: 10.1002/psp4.12109. Epub 2016 Sep 17.

11.

Linking MedDRA(®)-Coded Clinical Phenotypes to Biological Mechanisms by the Ontology of Adverse Events: A Pilot Study on Tyrosine Kinase Inhibitors.

Sarntivijai S, Zhang S, Jagannathan DG, Zaman S, Burkhart KK, Omenn GS, He Y, Athey BD, Abernethy DR.

Drug Saf. 2016 Jul;39(7):697-707. doi: 10.1007/s40264-016-0414-0.

12.

In Memoriam: David A. Flockhart, 1952-2015.

Greenblatt DJ, Abernethy DR.

J Clin Pharmacol. 2016 Apr;56(4):509-10. doi: 10.1002/jcph.726. Epub 2016 Feb 26. No abstract available.

PMID:
26919538
13.

Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4/5.

Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM.

Clin Pharmacol Ther. 2016 Jul;100(1):75-87. doi: 10.1002/cpt.337. Epub 2016 Mar 7.

14.

Bidirectional interactions between indomethacin and the murine intestinal microbiota.

Liang X, Bittinger K, Li X, Abernethy DR, Bushman FD, FitzGerald GA.

Elife. 2015 Dec 23;4:e08973. doi: 10.7554/eLife.08973.

15.

Elucidation of the molecular mechanisms underlying adverse reactions associated with a kinase inhibitor using systems toxicology.

Amemiya T, Honma M, Kariya Y, Ghosh S, Kitano H, Kurachi Y, Fujita KI, Sasaki Y, Homma Y, Abernethy DR, Kume H, Suzuki H.

NPJ Syst Biol Appl. 2015 Sep 28;1:15005. doi: 10.1038/npjsba.2015.5. eCollection 2015.

16.

Replication - why we need to publish our findings.

Curtis MJ, Abernethy DR.

Pharmacol Res Perspect. 2015 Aug;3(4):e00164. doi: 10.1002/prp2.164. Epub 2015 Jul 24.

17.

Logic-Based and Cellular Pharmacodynamic Modeling of Bortezomib Responses in U266 Human Myeloma Cells.

Chudasama VL, Ovacik MA, Abernethy DR, Mager DE.

J Pharmacol Exp Ther. 2015 Sep;354(3):448-58. doi: 10.1124/jpet.115.224766. Epub 2015 Jul 10.

18.

Hypothyroidism is a Risk Factor for New-Onset Diabetes: A Cohort Study.

Gronich N, Deftereos SN, Lavi I, Persidis AS, Abernethy DR, Rennert G.

Diabetes Care. 2015 Sep;38(9):1657-64. doi: 10.2337/dc14-2515. Epub 2015 Jun 12.

PMID:
26070591
19.

Adverse Event Detection and Labeling in Pediatric Drug Development: Antiretroviral Drugs.

Momper JD, Chang Y, Jackson M, Schuette P, Seo S, Younis I, Abernethy DR, Yao L, Capparelli EV, Burckart GJ.

Ther Innov Regul Sci. 2015 Mar;49(2):302-309. doi: 10.1177/2168479014565471.

PMID:
30222418
20.

Revision of instructions to authors for pharmacology research and perspectives: enhancing the quality and transparency of published work.

Curtis MJ, Abernethy DR.

Pharmacol Res Perspect. 2015 Mar;3(2):e00106. doi: 10.1002/prp2.106. No abstract available.

21.

Advice on statistical analysis, and new journal guidance for experimental design and analysis.

Curtis MJ, Abernethy DR.

Pharmacol Res Perspect. 2015 Feb;3(1):e00095. doi: 10.1002/prp2.95. No abstract available.

22.

Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support.

Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, Jones G, Brown ML, Grizzle AJ, Comes S, Wilkins TL, Borst C, Wittie MA, Malone DC.

Drug Saf. 2015 Feb;38(2):197-206. doi: 10.1007/s40264-014-0262-8.

23.

Application of systems pharmacology to explore mechanisms of hepatotoxicity.

Shon J, Abernethy DR.

Clin Pharmacol Ther. 2014 Nov;96(5):536-7. doi: 10.1038/clpt.2014.167.

PMID:
25336266
24.

Use of internet search logs to evaluate potential drug adverse events.

Sarntivijai S, Abernethy DR.

Clin Pharmacol Ther. 2014 Aug;96(2):149-50. doi: 10.1038/clpt.2014.115.

PMID:
25056395
25.

Drug Burden Index for international assessment of the functional burden of medications in older people.

Hilmer SN, Gnjidic D, Abernethy DR.

J Am Geriatr Soc. 2014 Apr;62(4):791-2. doi: 10.1111/jgs.12707. No abstract available.

PMID:
24731040
26.

The utility of modeling and simulation in drug development and regulatory review.

Huang SM, Abernethy DR, Wang Y, Zhao P, Zineh I.

J Pharm Sci. 2013 Sep;102(9):2912-23. doi: 10.1002/jps.23570. Epub 2013 May 24. Review.

PMID:
23712632
27.

A 2012 Workshop: Vaccine and Drug Ontology in the Study of Mechanism and Effect (VDOSME 2012).

He Y, Toldo L, Burns G, Tao C, Abernethy DR.

J Biomed Semantics. 2012 Dec 18;3(1):12. doi: 10.1186/2041-1480-3-12.

28.

Systems pharmacology to predict drug toxicity: integration across levels of biological organization.

Bai JP, Abernethy DR.

Annu Rev Pharmacol Toxicol. 2013;53:451-73. doi: 10.1146/annurev-pharmtox-011112-140248. Epub 2012 Nov 5. Review.

PMID:
23140241
29.

Needs for an expanded ontology-based classification of adverse drug reactions and related mechanisms.

Zhichkin PE, Athey BD, Avigan MI, Abernethy DR.

Clin Pharmacol Ther. 2012 Jun;91(6):963-5. doi: 10.1038/clpt.2012.41.

30.

High-risk prescribing and incidence of frailty among older community-dwelling men.

Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Cumming RG, Handelsman DJ, McLachlan AJ, Abernethy DR, Banks E, Le Couteur DG.

Clin Pharmacol Ther. 2012 Mar;91(3):521-8. doi: 10.1038/clpt.2011.258. Epub 2012 Feb 1.

PMID:
22297385
31.

Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation.

Zhao P, Vieira Mde L, Grillo JA, Song P, Wu TC, Zheng JH, Arya V, Berglund EG, Atkinson AJ Jr, Sugiyama Y, Pang KS, Reynolds KS, Abernethy DR, Zhang L, Lesko LJ, Huang SM.

J Clin Pharmacol. 2012 Jan;52(1 Suppl):91S-108S. doi: 10.1177/0091270011415528.

PMID:
22232759
32.

Integration of diverse data sources for prediction of adverse drug events.

Abernethy DR, Bai JP, Burkhart K, Xie HG, Zhichkin P.

Clin Pharmacol Ther. 2011 Nov;90(5):645-6. doi: 10.1038/clpt.2011.171.

PMID:
22012310
33.

Pharmacoepidemiology in the postmarketing assessment of the safety and efficacy of drugs in older adults.

Hilmer SN, Gnjidic D, Abernethy DR.

J Gerontol A Biol Sci Med Sci. 2012 Feb;67(2):181-8. doi: 10.1093/gerona/glr066. Epub 2011 Jun 8. Review.

PMID:
21653991
34.

Geriatric drug evaluation: where are we now and where should we be in the future?

Cho S, Lau SW, Tandon V, Kumi K, Pfuma E, Abernethy DR.

Arch Intern Med. 2011 May 23;171(10):937-40. doi: 10.1001/archinternmed.2011.152. Review.

PMID:
21606098
35.

Reducing drugs in older adults is more.

Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN.

Arch Intern Med. 2011 May 9;171(9):868-9. doi: 10.1001/archinternmed.2011.207. No abstract available.

PMID:
21555673
36.

Pharmacological mechanism-based drug safety assessment and prediction.

Abernethy DR, Woodcock J, Lesko LJ.

Clin Pharmacol Ther. 2011 Jun;89(6):793-7. doi: 10.1038/clpt.2011.55. Epub 2011 Apr 13. Review.

PMID:
21490594
37.

Drug burden index and beers criteria: impact on functional outcomes in older people living in self-care retirement villages.

Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN.

J Clin Pharmacol. 2012 Feb;52(2):258-65. doi: 10.1177/0091270010395591.

PMID:
21292625
38.

Pharmacogenomics and adverse drug reactions.

Amur S, Zineh I, Abernethy DR, Huang SM, Lesko LJ.

Per Med. 2010 Nov;7(6):633-642. doi: 10.2217/pme.10.63.

PMID:
29788561
39.

A pilot randomized clinical trial utilizing the drug burden index to reduce exposure to anticholinergic and sedative medications in older people.

Gnjidic D, Le Couteur DG, Abernethy DR, Hilmer SN.

Ann Pharmacother. 2010 Nov;44(11):1725-32. doi: 10.1345/aph.1P310. Epub 2010 Sep 28.

PMID:
20876826
40.

Effects of the physical work environment on physiological measures of stress.

Thayer JF, Verkuil B, Brosschot JF, Kampschroer K, West A, Sterling C, Christie IC, Abernethy DR, Sollers JJ, Cizza G, Marques AH, Sternberg EM.

Eur J Cardiovasc Prev Rehabil. 2010 Aug;17(4):431-9. doi: 10.1097/HJR.0b013e328336923a.

41.

Metal impurities in food and drugs.

Abernethy DR, Destefano AJ, Cecil TL, Zaidi K, Williams RL; USP Metal Impurities Advisory Panel.

Pharm Res. 2010 May;27(5):750-5. doi: 10.1007/s11095-010-0080-3. Epub 2010 Mar 9. Review.

PMID:
20217462
42.

Pediatric dose selection.

Abernethy DR, Burckart GJ.

Clin Pharmacol Ther. 2010 Mar;87(3):270-1. doi: 10.1038/clpt.2009.292. Review.

PMID:
20160747
43.

Effect of obesity on the pharmacokinetics of drugs in humans.

Hanley MJ, Abernethy DR, Greenblatt DJ.

Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000. Review.

PMID:
20067334
44.

Drug burden index score and functional decline in older people.

Hilmer SN, Mager DE, Simonsick EM, Ling SM, Windham BG, Harris TB, Shorr RI, Bauer DC, Abernethy DR; Health ABC Study.

Am J Med. 2009 Dec;122(12):1142-1149.e1-2. doi: 10.1016/j.amjmed.2009.02.021.

45.

Drug Burden Index and physical function in older Australian men.

Gnjidic D, Cumming RG, Le Couteur DG, Handelsman DJ, Naganathan V, Abernethy DR, Hilmer SN.

Br J Clin Pharmacol. 2009 Jul;68(1):97-105. doi: 10.1111/j.1365-2125.2009.03411.x.

46.

Change in criteria for USP dissolution performance verification tests.

Hauck WW, DeStefano AJ, Brown WE, Stippler ES, Abernethy DR, Koch WF, Williams RL.

AAPS PharmSciTech. 2009;10(1):21-6. doi: 10.1208/s12249-008-9169-y. Epub 2009 Jan 9.

47.

Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.

Woo AY, Wang TB, Zeng X, Zhu W, Abernethy DR, Wainer IW, Xiao RP.

Mol Pharmacol. 2009 Jan;75(1):158-65. doi: 10.1124/mol.108.051078. Epub 2008 Oct 7.

48.

Measures of drug toxicity in older adults.

Hilmer SN, Abernethy DR.

Arch Intern Med. 2008 Sep 22;168(17):1930-1; author reply 1931-2. doi: 10.1001/archinte.168.17.1930-c. No abstract available.

PMID:
18809825
49.

Metrologic approaches to setting acceptance criteria: unacceptable and unusual characteristics.

Hauck WW, Abernethy DR, Williams RL.

J Pharm Biomed Anal. 2008 Nov 4;48(3):1042-5. doi: 10.1016/j.jpba.2008.07.027. Epub 2008 Aug 9.

PMID:
18801635
50.

Finding the right research question: quality science depends on quality careers.

Flockhart DA, Abernethy DR.

Clin Pharmacol Ther. 2008 Sep;84(3):427-9. doi: 10.1038/clpt.2008.134. Epub 2008 Jul 9.

Supplemental Content

Loading ...
Support Center